Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 160

1.

Non-DNA-binding platinum anticancer agents: Cytotoxic activities of platinum-phosphato complexes towards human ovarian cancer cells.

Bose RN, Maurmann L, Mishur RJ, Yasui L, Gupta S, Grayburn WS, Hofstetter H, Salley T.

Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18314-9. doi: 10.1073/pnas.0803094105. Epub 2008 Nov 19. Erratum in: Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1292. Milton, Tara [corrected to Salley, Tara].

2.

Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.

Deqnah N, Yu JQ, Beale P, Fisher K, Huq F.

Anticancer Res. 2012 Jan;32(1):135-40.

PMID:
22213298
3.

Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter.

Helleman J, Burger H, Hamelers IH, Boersma AW, de Kroon AI, Stoter G, Nooter K.

Cancer Biol Ther. 2006 Aug;5(8):943-9. Epub 2006 Aug 2.

PMID:
16775422
5.

Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.

Alvarez-Valdés A, Pérez JM, López-Solera I, Lannegrand R, Continente JM, Amo-Ochoa P, Camazón MJ, Solans X, Font-Bardía M, Navarro-Ranninger C.

J Med Chem. 2002 Apr 25;45(9):1835-44.

PMID:
11960495
6.

Synthesis of trans-(4-hydroxypyridine)(ammine)dichloroplatinum(II) and its activity in the human ovarian tumour models.

Deqnah N, Qing Yu J, Beale P, Fisher K, Huq F.

Med Chem. 2013 Jun 1;9(4):539-44.

PMID:
23061563
7.

Role of carrier ligand in platinum resistance of human carcinoma cell lines.

Schmidt W, Chaney SG.

Cancer Res. 1993 Feb 15;53(4):799-805.

10.

Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.

Han I, Ling YH, al-Baker S, Khokhar AR, Perez-Soler R.

Cancer Res. 1993 Oct 15;53(20):4913-9.

11.
12.

Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.

Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L.

Cancer Chemother Pharmacol. 2011 Feb;67(2):401-14. doi: 10.1007/s00280-010-1334-9. Epub 2010 May 5.

14.

Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs.

Jansen BA, Brouwer J, Reedijk J.

J Inorg Biochem. 2002 Apr 28;89(3-4):197-202.

PMID:
12062123
15.

Cellular accumulation and cytotoxicity of macromolecular platinum complexes in cisplatin-resistant tumor cells.

Garmann D, Warnecke A, Kalayda GV, Kratz F, Jaehde U.

J Control Release. 2008 Oct 21;131(2):100-6. doi: 10.1016/j.jconrel.2008.07.017. Epub 2008 Jul 18.

PMID:
18691617
16.

Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.

Hamberger J, Liebeke M, Kaiser M, Bracht K, Olszewski U, Zeillinger R, Hamilton G, Braun D, Bednarski PJ.

Anticancer Drugs. 2009 Aug;20(7):559-72. doi: 10.1097/CAD.0b013e32832d513b.

PMID:
19491657
17.
18.

Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF.

Cancer Res. 1987 Jan 15;47(2):414-8.

19.

DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.

Delmastro DA, Li J, Vaisman A, Solle M, Chaney SG.

Cancer Chemother Pharmacol. 1997;39(3):245-53.

PMID:
8996528
20.

Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.

Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI.

Mol Pharmacol. 2000 Mar;57(3):503-11.

Supplemental Content

Support Center